These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19050206)

  • 41. Botulinum toxin. From poison to medical wonder.
    Mayo Clin Health Lett; 2006 Dec; 24(12):4-5. PubMed ID: 17310508
    [No Abstract]   [Full Text] [Related]  

  • 42. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
    Chapple C
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 44. Editorial comment on: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.
    Chapple C
    Eur Urol; 2009 Jan; 55(1):120. PubMed ID: 18823696
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
    Kim K; Shin HI; Kwon BS; Kim SJ; Jung IY; Bang MS
    Dev Med Child Neurol; 2011 Mar; 53(3):239-44. PubMed ID: 21087238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contralateral weakness following botulinum toxin for poststroke spasticity.
    Thomas AM; Simpson DM
    Muscle Nerve; 2012 Sep; 46(3):443-8. PubMed ID: 22907238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute neuromuscular failure related to long-term botulinum toxin therapy.
    Coletti Moja M; Dimanico U; Mongini T; Cavaciocchi V; Gerbino Promis PC; Grasso E
    Eur Neurol; 2004; 51(3):181-3. PubMed ID: 15073447
    [No Abstract]   [Full Text] [Related]  

  • 48. Botulinum toxin and human serum albumin.
    Malhotra R; Huilgol SC; Selva D
    Arch Ophthalmol; 2003 Nov; 121(11):1661; discussion 1661-2. PubMed ID: 14609937
    [No Abstract]   [Full Text] [Related]  

  • 49. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.
    Rajkumar GN; Conn IG
    Urology; 2004 Jul; 64(1):2-8. PubMed ID: 15245922
    [No Abstract]   [Full Text] [Related]  

  • 50. Aesthetic uses of botulinum toxin A.
    Niamtu J
    J Oral Maxillofac Surg; 1999 Oct; 57(10):1228-33. PubMed ID: 10513870
    [No Abstract]   [Full Text] [Related]  

  • 51. Botox for chronic migraine.
    Drug Ther Bull; 2011 Feb; 49(2):22-4; quiz iii-iv. PubMed ID: 21304165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of intra-articular injection of botulinum toxin type A in refractory hemiplegic shoulder pain.
    Castiglione A; Bagnato S; Boccagni C; Romano MC; Galardi G
    Arch Phys Med Rehabil; 2011 Jul; 92(7):1034-7. PubMed ID: 21704782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
    Bohluli B; Motamedi MH; Bagheri SC; Bayat M; Lassemi E; Navi F; Moharamnejad N
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jan; 111(1):47-50. PubMed ID: 20674409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [First experience of using lantox (botulinum toxin A) in chronic pelvic pain syndrome combined with bladder emptying dysfunction].
    Krivoborodov GG; Shumilo DV; Vasil'ev AV
    Urologiia; 2010; (2):60-2. PubMed ID: 20973143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of botulinum toxin to clinical therapy: advances and cautions.
    Levy NS; Lowenthal DT
    Am J Ther; 2012 Jul; 19(4):281-6. PubMed ID: 22481607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache.
    Ahmed K; Oas KH; Mack KJ; Garza I
    Pediatr Neurol; 2010 Nov; 43(5):316-9. PubMed ID: 20933173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re: Botulinum toxin for the treatment of facial flushing.
    Kranendonk SK; Ferris LK; Obagi S
    Dermatol Surg; 2005 Apr; 31(4):491; author reply 492. PubMed ID: 15871333
    [No Abstract]   [Full Text] [Related]  

  • 58. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Neumeister MW
    J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia.
    Pelletier F; Parratte B; Penz S; Moreno JP; Aubin F; Humbert P
    Br J Dermatol; 2011 Mar; 164(3):617-22. PubMed ID: 21275944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum toxin A in anti-GAD-positive stiff-limb syndrome.
    Anagnostou E; Zambelis T
    Muscle Nerve; 2012 Sep; 46(3):457-8. PubMed ID: 22907242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.